Literature DB >> 26014961

HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a).

Calvin Yeang1, Sotirios Tsimikas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26014961      PMCID： PMC4479328          DOI： 10.1194/jlr.E060947

Source DB:  PubMed          Journal:  J Lipid Res        ISSN： 0022-2275            Impact factor:   5.922


× No keyword cloud information.
  47 in total

1.  A NEW SERUM TYPE SYSTEM IN MAN--THE LP SYSTEM.

Authors:  K BERG
Journal:  Acta Pathol Microbiol Scand       Date:  1963

2.  Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a].

Authors:  William J Cain; John S Millar; Adam S Himebauch; Uwe J F Tietge; Cyrille Maugeais; David Usher; Daniel J Rader
Journal:  J Lipid Res       Date:  2005-09-08       Impact factor: 5.922

3.  Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.

Authors:  Sotirios Tsimikas; Emmanouil S Brilakis; Elizabeth R Miller; Joseph P McConnell; Ryan J Lennon; Kenneth S Kornman; Joseph L Witztum; Peter B Berger
Journal:  N Engl J Med       Date:  2005-07-07       Impact factor: 91.245

4.  The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor.

Authors:  K M Argraves; K F Kozarsky; J T Fallon; P C Harpel; D K Strickland
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

5.  Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro.

Authors:  A Niemeier; T Willnow; H Dieplinger; C Jacobsen; N Meyer; J Hilpert; U Beisiegel
Journal:  Arterioscler Thromb Vasc Biol       Date:  1999-03       Impact factor: 8.311

6.  Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study.

Authors:  K Berg; G Dahlén; B Christophersen; T Cook; J Kjekshus; T Pedersen
Journal:  Clin Genet       Date:  1997-11       Impact factor: 4.438

7.  Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins.

Authors:  S Hörkkö; D A Bird; E Miller; H Itabe; N Leitinger; G Subbanagounder; J A Berliner; P Friedman; E A Dennis; L K Curtiss; W Palinski; J L Witztum
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

8.  A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma.

Authors:  Claes Bergmark; Asheesh Dewan; Alexina Orsoni; Esther Merki; Elizabeth R Miller; Min-Jeong Shin; Christoph J Binder; Sohvi Hörkkö; Ronald M Krauss; M John Chapman; Joseph L Witztum; Sotirios Tsimikas
Journal:  J Lipid Res       Date:  2008-07-01       Impact factor: 5.922

9.  Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study.

Authors:  Stefan Kiechl; Johann Willeit; Manuel Mayr; Brigitte Viehweider; Martin Oberhollenzer; Florian Kronenberg; Christian J Wiedermann; Sabine Oberthaler; Qingbo Xu; Joseph L Witztum; Sotirios Tsimikas
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-05-31       Impact factor: 8.311

10.  In search of a biological pattern for human longevity: impact of apo A-IV genetic polymorphisms on lipoproteins and the hyper-Lp(a) in centenarians.

Authors:  G Pepe; V Di Perna; F Resta; M Lovecchio; G Chimienti; A M Colacicco; A Capurso
Journal:  Atherosclerosis       Date:  1998-04       Impact factor: 5.162
View more
  2 in total

1.  Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.

Authors:  Reinhard Klingel; Andreas Heibges; Cordula Fassbender
Journal:  Clin Res Cardiol Suppl       Date:  2017-03

2.  Effect of a PCSK9 inhibitor and a statin on cholesterol efflux capacity: A limitation of current cholesterol-lowering treatments?

Authors:  Qidi Ying; Annalisa Ronca; Dick C Chan; Jing Pang; Elda Favari; Gerald F Watts
Journal:  Eur J Clin Invest       Date:  2022-03-24       Impact factor: 5.722
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.